Chronic Fatigue Syndrome and Myalgic Encephalomyelitis Studies

Chronic Fatigue Syndrome (CFS) and Myalgic Encephalomyelitis (ME) represent disabling, often lifelong conditions characterised by profound fatigue, post-exertional symptom exacerbation, cognitive impairment and a constellation of autonomic, immune and metabolic abnormalities. Recognition has grown of the heterogeneity and potential subgroups within ME/CFS, reflecting divergent pathophysiological mechanisms. Epidemiological studies estimate prevalence at around 0.2–0.7% in the general population, with a female to male ratio of approximately 3:1 and a peak onset between 20 and 40 years of age. Although the precise aetiology remains elusive, accumulating evidence points to immune dysregulation, autoantibody production, mitochondrial dysfunction and microbial disturbances in the gut–brain–immune axis. Neurological features include cognitive slowing, orthostatic intolerance and dysautonomia, while vascular pathology manifests as endothelial dysfunction and coagulation anomalies. Current diagnosis relies on clinical criteria of exclusion, underscoring the urgent need for objective biomarkers. Research efforts now span multi-omics profiling, immunophenotyping and advanced imaging to delineate subtypes and inform targeted interventions. International collaborations aim to standardise case definitions and outcome measures, facilitating reproducibility and translational research. Advances in molecular signatures offer promise for diagnostic assays and personalised therapeutics, with potential relevance for related post-infectious syndromes such as long COVID.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Chronic Fatigue Syndrome and Myalgic Encephalomyelitis Studies publication trend

The graph below shows the total number of articles in chronic fatigue syndrome and myalgic encephalomyelitis studies across all publications each year (not limited to Nature Index journals).

Technical terms

Dysbiosis: imbalance in the composition and function of the gut microbiome, often associated with altered host metabolism and immune responses.

Butyrate: a short-chain fatty acid produced by certain gut bacteria that supports intestinal barrier integrity and modulates immune activity.

Peripheral blood mononuclear cells (PBMCs): immune cells isolated from blood, including lymphocytes and monocytes, used for diagnostic assays and functional studies.

Endothelial dysfunction: impaired function of the vascular endothelium, leading to abnormal blood vessel regulation and potential coagulopathy.

Post-exertional symptom exacerbation (PESE): a hallmark of ME/CFS characterised by a marked worsening of symptoms following minimal physical or cognitive effort.

Metabolomics: comprehensive analysis of small-molecule metabolites within biological samples, offering insights into altered metabolic pathways.

References

1. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host & Microbe (2023).
2. Developing a Blood Cell‐Based Diagnostic Test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Using Peripheral Blood Mononuclear Cells. Advanced Science (2023).
3. Data-independent LC-MS/MS analysis of ME/CFS plasma reveals a dysregulated coagulation system, endothelial dysfunction, downregulation of complement machinery. Cardiovascular Diabetology (2024).
4. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Journal of Translational Medicine (2020).
5. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease. Autoimmunity Reviews (2018).